Table 4 Patients demographics.
From: Enhanced neutrophil apoptosis accompanying myeloperoxidase release during hemodialysis
n | 70 |
Age (years old) | 63 ± 15.4 |
Male (%) | 51 (73) |
Dialysis vintage (months) | 18 (1–391) |
Pre-HD body weight (kg) | 60.3 ± 14.5 |
BMI (kg/m2) | 23.1 ± 4.8 |
Underlying kidney disease (%) | |
Diabetic kidney disease | 28 (40) |
Nephrosclerosis | 12(17) |
Glomerulonephritis | 13(19) |
Others | 17 (24) |
Comorbidities (%) | |
CVD | 28 (40) |
Current cancer | 18 (26) |
Apoplexy | 13 (19) |
Dialysis period (%) | |
Initiation (< 3 months) | 25 (36) |
Maintenance | 45 (64) |
Dialysis membrane | |
PMMA (%) | 16 (23) |
PS (%) | 54 (77) |
Laboratory data (Pre-HD) | |
WBC (/μL) | 6142 ± 2474 |
Hemoglobin (g/dL) | 9.9 ± 1.3 |
Platelet (× 104/μL) | 19.2 ± 8.1 |
Total protein (g/dL) | 6.2 ± 0.8 |
Albumin (g/dL) | 2.8 ± 0.6 |
BUN (mg/dL) | 56 ± 25 |
Creatinine (mg/dL) | 8.91 ± 2.89 |
Na (mEq/L) | 136 ± 4 |
K (mEq/L) | 4.1 ± 0.6 |
Cl (mEq/L) | 104 ± 4 |
Calcium (mg/dL) | 8.5 ± 0.8 |
Phosphate (mg/dL) | 5.2 ± 1.6 |
CRP (mg/dL) | 2.11 ± 4.71 |
β2- microglobulin (mg/L) | 24.8 ± 7.5 |
